EX-99.1 2 asmb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates - Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) - - Completed $115 million gross financing to support advancement of pipeline programs through key development milestones - - GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 - - Cash runway projected into 2029, including first $75 million Gilead collaboration extension payment due in Q4 2026 - SOUTH SAN FRANCISCO, Calif. - August 13, 2026 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today reported financial results for the second quarter ended June 30, 2026, and recent business updates. “During the second quarter, we advanced several important strategic priorities, including expanding ABI-6250 into cholestatic liver diseases and strengthening our balance sheet through a successful financing to support the …
Open exhibit ↗Current Report · Items 2.01, 9.01 · 8-K
Assembly Biosciences, Inc.
ASMBNASDAQEQUITYCurrent
Completion of Acquisition or Disposition of Assets
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description Number ──────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release dated August 13, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Company context
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesvirus, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV). For more information, visit assemblybio.com.